Drugs and patents in ATC class P02D

Last updated: February 19, 2026

This report analyzes the patent landscape and market dynamics for anticestodal drugs, classified under ATC code P02D. The market is characterized by limited new drug development and reliance on established compounds. Patent expirations are a significant factor, leading to generic competition and price erosion for older treatments.

What is the Current Market Size and Growth Projection for Anticestodals?

The global market for anticestodals is relatively small and exhibits modest growth. This is primarily due to the limited incidence of cestode infections in developed countries and the availability of effective, off-patent generic treatments.

Market Size: The market for anticestodals is estimated to be in the tens of millions of U.S. dollars globally. Precise figures are challenging to ascertain due to the niche nature of the segment and its inclusion within broader anthelmintic drug categories.
Growth Drivers: Growth is primarily driven by veterinary applications, particularly in livestock management where parasitic infections can impact productivity. In human medicine, the market is largely sustained by its presence on essential medicines lists and its use in regions with higher endemicity.
Growth Rate: Projected annual growth rates are low, typically in the low single digits (1-3%), reflecting a mature market with limited innovation.
Geographic Concentration: While cestode infections can occur globally, human treatment markets are more concentrated in developing countries where sanitation and hygiene practices may be less advanced. Veterinary markets are global, driven by the livestock industry.

What are the Key Anticestodal Drugs and Their Patent Status?

The anticestodal drug market is dominated by a few established compounds, many of which have experienced patent expiries, leading to significant generic penetration.

Drug Name	ATC Code	Primary Mechanism of Action	Key Indications	Current Patent Status	Generic Availability
Praziquantel	P02BA01	Increases cell membrane permeability to calcium ions.	Taenia spp., Echinococcus granulosus, Diphyllobothrium latum, Schistosomiasis (off-label use)	Original patents expired.	High
Niclosamide	P02CA03	Uncouples oxidative phosphorylation.	Taenia spp., Diphyllobothrium latum, Hymenolepis nana	Original patents expired.	High
Albendazole	P02CA03	Inhibits microtubule polymerization.	Taenia spp., Echinococcus granulosus (hydatid disease), various nematodes	Original patents expired. Formulations and specific uses may have later patents.	High
Mebendazole	P02CA04	Inhibits microtubule polymerization.	Taenia spp., Echinococcus granulosus (hydatid disease), various nematodes	Original patents expired. Formulations and specific uses may have later patents.	High

Praziquantel: This is a cornerstone treatment for many cestode infections and schistosomiasis. Its broad spectrum of activity and good safety profile have ensured its continued use. While the original composition of matter patents have long expired, there may be patents related to specific formulations, delivery systems, or manufacturing processes. For instance, the development of oral suspensions or novel co-formulations could be patentable.
Niclosamide: Historically important for tapeworm infections, its use has somewhat decreased in favor of praziquantel for certain indications. Patent protection has expired, leading to widespread generic availability.
Benzimidazoles (Albendazole, Mebendazole): These drugs are primarily known for their efficacy against nematodes but also possess activity against certain cestodes like Taenia species and Echinococcus granulosus. Their patent status is similar to praziquantel; the core compounds are off-patent, but advancements in drug delivery, combination therapies, or specific indications might be protected. For example, patents might cover extended-release formulations or novel combinations with other anthelmintics.

What is the Patent Landscape for New Anticestodal Drug Development?

The patent landscape for new anticestodal drug development is sparse, reflecting limited research and development (R&D) investment in this specific therapeutic area.

Limited Novel Compound Patents: There are few recent patent filings for novel chemical entities specifically targeting cestodes. The majority of active patents are likely related to:
- Formulations and Delivery Systems: Enhancements to existing drugs, such as improved bioavailability, extended-release profiles, or pediatric-friendly formulations.
- New Indications for Existing Drugs: Repurposing or expanding the approved uses of known anticestodal compounds or drugs with antiparasitic properties.
- Combination Therapies: Patents covering the synergistic use of two or more existing drugs to enhance efficacy or overcome resistance.
- Manufacturing Processes: Novel or more efficient methods for synthesizing established anticestodal agents.
Veterinary Focus: A greater proportion of R&D and patent activity, albeit still limited, might be observed in the veterinary sector, driven by the economic impact of parasitic infections in livestock.
Emerging Resistance Concerns: While not yet a widespread crisis for cestodes compared to some nematodes or bacteria, emerging resistance could spur R&D. However, patent filings in this area are not yet prominent.
Global Health Initiatives: Research funded by global health organizations may lead to patent filings, but these are often focused on ensuring accessibility rather than creating new market exclusivity for blockbuster drugs.

What are the Key Challenges and Opportunities in the Anticestodal Market?

The anticestodal market presents distinct challenges and limited but specific opportunities.

Challenges:

Limited R&D Investment: The relatively small market size and the availability of cheap generics disincentivize significant investment in discovering and developing new anticestodal drugs for human use.
Patent Expirations: Most key anticestodal drugs are off-patent, leading to intense generic competition and low profit margins for manufacturers of the active pharmaceutical ingredient (API).
Drug Resistance: While less prevalent than in other parasitic classes, the potential for resistance to existing drugs is a growing concern that could necessitate new treatments.
Diagnostic Limitations: Accurate and rapid diagnosis of specific cestode infections can be challenging in resource-limited settings, impacting treatment selection and market demand.
Regulatory Hurdles: For new drug applications, demonstrating significant therapeutic advantage over existing, inexpensive generics can be a high bar for regulatory approval.

Opportunities:

Improved Formulations: Developing novel formulations of existing drugs (e.g., enhanced solubility, palatability for children, extended-release) could offer patentable intellectual property and differentiation.
Combination Therapies: Identifying and patenting synergistic combinations of existing anticestodals or repurposing other drugs could provide enhanced efficacy or broader spectrum activity.
Veterinary Market Expansion: Opportunities exist for developing more targeted or cost-effective anticestodal treatments for livestock, addressing specific parasitic burdens in different animal species and geographical regions.
Neglected Tropical Diseases (NTDs) Focus: Grants and initiatives aimed at combating NTDs, such as cysticercosis and echinococcosis, may provide funding and support for research into new or improved anticestodal therapies, potentially leading to patentable discoveries.
Repurposing Opportunities: Screening libraries of existing drugs for anticestodal activity could uncover new therapeutic candidates with existing safety profiles, reducing development time and cost.

What is the Competitive Landscape for Anticestodals?

The competitive landscape is dominated by generic manufacturers, with a few multinational pharmaceutical companies holding specific patent-protected formulations or niche veterinary products.

Generic Manufacturers: The primary competition comes from generic API producers and finished dosage form manufacturers, predominantly based in India and China, who supply the global market at highly competitive prices.
API Suppliers: Companies specializing in the synthesis of praziquantel, niclosamide, albendazole, and mebendazole are key players. Their ability to produce at scale and low cost is crucial for market share.
Branded Products (Limited): Branded formulations of these drugs exist but hold a small market share due to the price advantage of generics. For example, specific pediatric formulations or combinations might retain some branded market presence.
Veterinary Product Manufacturers: Companies like Boehringer Ingelheim, Zoetis, and Merck Animal Health offer a range of anthelmintic products, some of which include anticestodal activity, often targeting livestock. These may be protected by formulation patents or specific veterinary indications.
Contract Manufacturing Organizations (CMOs): CMOs play a significant role in the production of generic anticestodals for various clients.

What are the Key Patent Trends and Filing Activities?

Patent filing activity in the anticestodal space is minimal, with a focus on incremental innovations rather than breakthrough discoveries.

Low Filing Volume: The overall number of new patent applications related to anticestodals is low. The therapeutic area is not a focus for major pharmaceutical R&D pipelines.
Focus on Existing Molecules: Patents are predominantly filed for:
- New Formulations: E.g., solid dispersions for improved dissolution, microencapsulation for controlled release, or novel oral suspensions.
- Combination Products: Patents protecting the combination of an anticestodal with another drug to enhance efficacy or address co-infections.
- Manufacturing Processes: Improvements in the synthesis of praziquantel or benzimidazoles that offer cost savings or environmental benefits.
- Repurposed Drugs: Patenting the use of non-anticestodal drugs for treating cestode infections based on new research.
Geographic Filing: Patent filings are more likely to occur in major pharmaceutical markets (US, EU, Japan) and key manufacturing hubs (e.g., India, China) if the innovation is commercially significant. However, given the market's nature, extensive global filings for minor formulation improvements are less common.
Academic and NGO Involvement: A small number of patent applications may originate from academic institutions or non-governmental organizations, often related to basic research or public health initiatives. These patents may then be licensed to manufacturers.
Lack of "Game-Changing" Patents: There are no recent, broad patent filings that suggest the imminent introduction of a fundamentally new class of anticestodal drugs.

Key Takeaways

The anticestodal market (ATC P02D) is mature, characterized by a lack of novel drug development and a strong reliance on off-patent, generic medications. Praziquantel, niclosamide, albendazole, and mebendazole remain the principal treatments. Competition is driven by low-cost generic manufacturers, particularly for API production. Patent activity is minimal and primarily focused on incremental improvements such as new formulations, delivery systems, or combination therapies for existing molecules. Opportunities for innovation lie in these areas, alongside veterinary applications and research supported by global health initiatives addressing neglected tropical diseases. The market's small size and low profit margins disincentivize significant investment in groundbreaking R&D for human therapeutics.

Frequently Asked Questions

What is the primary driver for current anticestodal drug sales? Anticestodal drug sales are primarily driven by veterinary applications, especially in livestock, and by their use in developing countries where cestode infections are more endemic.
Are there any new anticestodal drugs in late-stage clinical development? There are very few, if any, novel anticestodal drugs in late-stage clinical development for human use. The focus remains on optimizing existing treatments.
How significant is drug resistance in cestode infections? Drug resistance is not yet a major clinical issue for most common cestode infections, unlike some other parasitic diseases. However, it remains a potential long-term concern.
What is the patentability of improved praziquantel formulations? Improved praziquantel formulations, such as those with enhanced bioavailability, palatability, or extended-release properties, can be patentable if they demonstrate novelty and inventiveness.
Which regions are most active in anticestodal patent filings? Patent filings are sparse but would typically be found in major pharmaceutical markets like the United States and Europe, and in key manufacturing centers such as India and China, reflecting commercial interests.

Citations

[1] World Health Organization. (2023). WHO Model List of Essential Medicines. Retrieved from https://www.who.int/publications/i/item/9789240071051 [2] European Medicines Agency. (n.d.). Antiparasitic products. Retrieved from relevant EMA publications and databases. [3] U.S. Food & Drug Administration. (n.d.). Drug Shortages. Retrieved from FDA drug shortage information. [4] Global burden of parasitic diseases reports from organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). (Specific reports vary by year and focus). [5] Market research reports on anthelmintic and antiparasitic drug markets from firms such as Grand View Research, Mordor Intelligence, and Allied Market Research. (These reports are typically proprietary and require subscription for full access).

Drugs in ATC Class P02D

Subclasses in ATC: P02D - ANTICESTODALS

Patent Landscape and Market Dynamics for Anticestodals (ATC Class P02D)